Patients with Covid-19 in the NHS will also be given the HIV combination therapy Lopinavir-Ritonavir, alongside low-dose corticosteroids, to assess if these treatments are effective against the virus.
The funding comes from UK Research and Innovation (UKRI) and will go towards developing a new vaccine for Covid-19; furthering manufacturing processing for mass-producing vaccines; testing existing drugs against Covid-19; developing new therapeutic antibodies; and collecting data on Covid-19 patients.
The government has confirmed clinical trials to find a vaccine for COVID-19 have begun, at a current cost of £20 million.
Whether testing new drugs or examining how to repurpose existing ones, United Kingdom scientists and researchers have been working tirelessly on the development of treatments for coronavirus.
"The projects we are funding today will be vital in our work to support our valuable NHS and protect people's lives". Vaccines are still likely at least a year out from approvals, though some have already entered into clinical human trials at unprecedented speed owing to the unprecedented nature of the pandemic.
Now experts from the Center for Vaccine Research at the University of Pittsburgh are testing out a new experimental vaccine that was developed from an existing measles vaccine.
Clinical trials help doctors understand how to treat a particular illness.
"Amid a global health emergency, the U.K.is using all its extensive research expertise to develop new vaccines to target this worldwide threat quickly".
The U.K. government will fund the six new projects, including others developing antibodies to help target the virus, examining how people at the highest risk could be identified, and how existing treatments can be used for the treatment of the coronavirus disease (COVID-19).
This kind of tracker is a good resource for anyone looking to keep tabs on the ongoing work that people are doing to take on COVID-19, though it's a high-level view that is probably of most interest to other ongoing projects, as well as health and research professionals who might be able to assist in the development of these solutions, or to collaborate with partners.
Jennifer Haller was the first person to be injected with the trial vaccine. The trial will have an "adaptive" design, meaning it can test new therapies as they become available. They are working with Professor Sarah Gilbert's team, who are developing promising novel coronavirus vaccines by modifying harmless adenoviruses.
A further £0.3 million funding will go to a project under Profs Ultan Power and Ken Mills from Queens University Belfast who are testing a library of around 1,000 human-use approved drugs on cells in the laboratory. The drugs are already approved for use in humans.